Changes in use of disease-modifying anti-rheumatic drugs in Australia over the period 1992-2004

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 7, 2006, Pages 462-468

  Chan, Vivien ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Defined daily dose; Disease modifying anti rheumatic drugs; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; CHLOROQUINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; AUSTRALIA; CALCULATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG USE; DRUG UTILIZATION; GENERAL PRACTITIONER; HEALTH PROGRAM; HUMAN; INTERMETHOD COMPARISON; MEDICAL SPECIALIST; METHODOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS;

ANTIRHEUMATIC AGENTS; AUSTRALIA; DRUG UTILIZATION; HUMANS; TIME FACTORS;

EID: 33746647756     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1256     Document Type: Article

References (38)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328-346.
2. O'Gradaigh D, Scott DGI. Pyramids to myriads: the combination conundrum in rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: S13-S19.
3. Horsfall MWJ, Shaw JP, Highton J, Cranch PJ. Changing patterns in the use of slow acting antirheumatic drugs for the treatment of rheumatoid arthritis. NZ Med J 1998; 111: 200-203.
4. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991; 18: 1290-1297.
5. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-2213.
6. van der Heide A, Jacobs JWG, Bijlsma JWJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124: 699-707.
7. Stenger AAME, van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998; 37: 1157-1163.
8. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000; 27: 623-629.
9. Verstappen SM, Jacobs JWG, Bijlsma JWJ, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003; 48: 1797-1807.
10. Maravic M, Berge C, Daures JP, Boissier MC. Survey of practices regarding management of early rheumatoid arthritis by rheumatologists in France. Clin Exp Rheumatol 2004; 22(3): 319-327.
11. Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology (Oxford) 2004; 43(2): 206-210.
12. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004; 63(10): 1269-1275.
13. Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum 2002; 47(3): 285-290.
14. Baum SK, Tracy IC, Henderson EH, Alarcón GS. Combination of disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. A survey of Alabama rheumatologists. Arthritis Care Res 1991; 4: 48-51.
15. Bjelle A, Mjörndal T. Drug prescription patterns for rheumatic disorders in Sweden. J Rheumatol 1984; 11: 493-499.
16. Blomqvist P, Feltelius N, Ekbom A, Klareskog L. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions. J Rheumatol 2000; 27: 1171-1177.
17. Ward MM. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Medical Care Surveys. J Rheumatol 1999; 26: 546-550.
18. Conaghan PG, Crotty M, Oh E, Day RO, Brooks PM. Antirheumatic drug-prescribing behaviour of Australasian rheumatologists 1984-1994. Br J Rheumatol 1997; 36: 487-490.
19. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J Rheumatol 2002; 29: 255-260.
20. Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003; 30: 697-704.
21. Galindo-Rodriguez G, Avina-Zubieta JA, Fitzgerald A, LeClerq SA, Russell AS, Suarez-Almazor ME. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis. J Rheumatol 1997; 24: 633-638.
22. Health Insurance Commission. Pharmaceutical Benefits Schedule item statistics. Available at: http://www.hic.gov.au/statistics/dyn_pbs/forms/ pbs_tab1.shtml [Accessed 24 June 2005].
23. World Health Organisation Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 5th Edition. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2002.
24. Australian Bureau of Statistics. Australian Demographic Statistics Quarterly. Canberra: Australian Bureau of Statistics; ABS catalogue no. 3101.0 [accessed on-line using AusStats, 24 June 2005]
25. World Health Organisation Collaborating Centre for Drugs Statistics Methodology. ATC index with DDDs 2005. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2005.
26. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Pharmaceutical Society of Australia, Royal Australian College of General Practitioners. Australian Medicines Handbook 2004, 5th edition. Adelaide: Australian Medicines Handbook Pty Ltd; 2004.
27. Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 1997; 27: 123-140.
28. Australian Institute of Health and Welfare. Australia's Health 2004: the ninth biennial health report of the Australian Institute of Health and Welfare (AIHW catalogue no. AUS44). 2004. Available at: http://www.aihw.gov.au/publications/index.cfm/title/10014 [Accessed 27 July 2005].
29. Osiri M, Akkasilpa S, Deesomchok U. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study. J Med Assoc Thai 2000; 83: 217-224.
30. Zink A, Listing J, Niewerth M, Zeidler H. The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 207-213.
31. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002; 29: 1631-1638.
32. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41: 1367-1374.
33. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002; 29: 2521-2524.
34. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990; 33: 1449-1461.
35. Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J Rheumatol 2002; 29: 261-266.
36. American College of Rheumatology. Patient education: disease-specific information. Available at: http://www.rheumatology.org/public/factsheets/ index.asp?aud=pat [Accessed 23 June 2004].
37. Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol 1996; 35: 1289-1291.
38. Kaipiainen-Seppanen O, Aho K, Heliovaara M. Incidence and prevalence of ankylosing spondylitis in Finland. J Rheumatol 1997; 24: 496-499.